Filing Flows › Health Care › Teleflex (TFX)
Teleflex (TFX) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Teleflex (TFX) Q3 2026 earnings results →
Q3 2026 Revenue up 0% year over year to $568M · 163¢ of every $1 of revenue kept as net profit · operating margin 18.6%
Teleflex made $568M in Q3 2026 (+0.1% Y/Y): Vascular $243M, Interventional $210M, Surgical $114M. Operating margin 18.6%, net earnings $927M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $567.8M in Q3 2026, roughly flat year over year and roughly flat from the previous quarter. Vascular was the largest line at 43% of revenue. Vascular added $10.9M year over year (up 5%), 1306% of the total change. Interventional declined 3%.
Gross margin was 65.0%, up 13.4 points from Q3 2025. Operating profit was $105.4M, a 18.6% margin (up 29.6 points year over year). Operating expenses fell 26% while revenue was flat. Net earnings were $927.4M. The effective tax rate was 3.0%. Non-operating items added $850.8M, 89% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $96.3M (up 392% year over year), 10% of net earnings. Non-cash charges added back $51.6M of depreciation and amortization and $6.3M of share-based compensation. Working capital and other items used $889.0M. Capital expenditures of $21.6M left free cash flow of $74.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $568M | +0.1% | 18.6% | $927M | $96.3M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $570M | +29% | 12.8% | $99.7M | $91.9M |
| Q1 2026 | 10-Q | May 7, 2026 | $548M | +32% | 3.7% | −$8.2M | $46.7M |
| Q4 2025 | 10-K | Feb 27, 2026 | $569M | +29% | 2.4% | −$714M | −$92.3M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $913M | +19% | -44.8% | −$409M | $108M |
| Q2 2025 | 10-Q | Jul 31, 2025 | $781M | +4% | 19.9% | $123M | $7.8M |
| Q1 2025 | 10-Q | May 1, 2025 | $701M | -5% | 17.9% | $95.0M | $73.3M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Teleflex
Teleflex is a global provider of medical technology products that enhance clinical benefits, improve patient and provider safety and reduce total procedural costs. We primarily design, develop, manufacture and supply single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. We market and sell our products to hospitals and healthcare providers worldwide through a combination of our direct sales force and distributors. Because our products are used in numerous markets and for a variety of procedures, we are not dependent upon any one end-market or procedure. Our major manufacturing operations are located in the Czech Republic, Malaysia, Mexico and the United States (the "U.S.").
In its own words, from its 10-K, filed Feb 27, 2026.
Teleflex against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +0.1% against the peers' median +5%. Operating margin: 18.6% against the peers' median 15.9%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| TFX Teleflex | Q3 2026 | $568M | +0.1% | 18.6% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Teleflex 10-Q on SEC EDGAR · CIK 96943 · Surgical & Medical Instruments & Apparatus
Guidance and outlook
13F: who owns TFX and who is buying
More on TFX
- How Teleflex makes money: revenue by segment
- Teleflex next earnings date and what analysts expect
- Teleflex stock forecast, price target and fair value
- Who owns Teleflex stock: holders, funds and Congress trades
- Teleflex guidance and outlook
- Is Teleflex a takeover target? LBO and rumors
- Teleflex recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- Teleflex guidance history: guided vs reported
- Teleflex gross margin by quarter
- Teleflex operating margin by quarter
- Teleflex net income by quarter
- Teleflex free cash flow by quarter
- Teleflex R&D spending by quarter
- Teleflex capital expenditures by quarter
- Teleflex Interventional revenue by quarter
- Teleflex Surgical revenue by quarter